Jeong-Min Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jeong-Min Lee has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Kun-Ho Song
Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Republic of Korea
10 shared publications - Joong-Hyun Song
College of Veterinary Medicine, Chungnam National University
7 shared publications - Hee-Tae Park
Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Korea
2 shared publications - Ji-Young Lee
Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon34134, Republic of Korea
2 shared publications - Jin-Young Kim
Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon 34143, South Korea
2 shared publications - Jiwoong Her
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (6)
Esophageal strictures associated with prolonged nasoesophageal tube placement in three cats
Nasoesophageal tube placement for a prolonged period of time has not previously been associated with esophageal stricture in cats. Three cats with suspected hepatic lipidosis required extended enteral nutritional support because voluntary food intake remained < 25% of the calculated resting energy requirement. The cumulative duration of nasoesophageal tube placement was 24-37 days. Regurgitation or retching developed within 1-3 days after tube removal, and esophagoscopy identified severe focal strictures in the cervical esophagus at the C4-C6 vertebral level in all 3 cats. One cat underwent 3 endoscopic balloon dilatation sessions at 1-week intervals, with enlargement of the esophageal lumen. The consistent anatomic location and temporal association with prolonged tube placement suggest that extended nasoesophageal intubation may be a risk factor for cervical esophageal stricture formation in cats. When prolonged nutritional support is anticipated, transition to a feeding tube intended for long-term use should be considered.
- 2 November 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (6)
Open AccessEsophageal strictures associated with prolonged nasoesophageal tube placement in three cats
Nasoesophageal tube placement for a prolonged period of time has not previously been associated with esophageal stricture in cats. Three cats with suspected hepatic lipidosis required extended enteral nutritional support because voluntary food intake remained < 25% of the calculated resting energy requirement. The cumulative duration of nasoesophageal tube placement was 24-37 days. Regurgitation or retching developed within 1-3 days after tube removal, and esophagoscopy identified severe focal strictures in the cervical esophagus at the C4-C6 vertebral level in all 3 cats. One cat underwent 3 endoscopic balloon dilatation sessions at 1-week intervals, with enlargement of the esophageal lumen. The consistent anatomic location and temporal association with prolonged tube placement suggest that extended nasoesophageal intubation may be a risk factor for cervical esophageal stricture formation in cats. When prolonged nutritional support is anticipated, transition to a feeding tube intended for long-term use should be considered.
- Open Access
- 17 August 2026
- Published by MDPI AG in Preprints.org
Hematologic and Renal Trends in Cats Undergoing Continuous Renal Replacement Therapy with Adjunctive Molidustat Administration: A Retrospective Case Series
Continuous renal replacement therapy (CRRT) can precipitate anemia in critically ill patients, but temporal hematologic trends and anemia management strategies in cats remain poorly characterized. Medical records of three client-owned cats treated with CRRT for severe acute kidney injury with evidence of pre-existing chronic kidney disease at a single referral center were retrospectively reviewed. Hematologic variables (hematocrit, hemoglobin concentration, absolute reticulocyte count) and renal parameters (blood urea nitrogen, creatinine, phosphorus) were evaluated before, during, and after CRRT, along with the timing of CRRT sessions, whole blood transfusions, erythropoiesis-stimulating agent administration, and adjunctive molidustat use. All three cats demonstrated a progressive decline in hematocrit during the CRRT period despite repeated whole blood transfusions, with only transient post-transfusion improvement. Blood urea nitrogen and creatinine concentrations decreased promptly following CRRT initiation but showed variable rebound patterns during follow-up. Absolute reticulocyte counts increased after CRRT discontinuation in two cats, indicating preserved or recovering erythropoietic activity, while one cat with concurrent systemic inflammation showed a minimal response. Progressive anemia occurred consistently despite transfusion support, highlighting the multifactorial nature of anemia during feline CRRT. These descriptive findings provide clinically relevant insight into anemia progression during feline CRRT and may inform the design of future prospective studies.
- 17 August 2026
- Published by MDPI AG in Preprints.org
Open AccessHematologic and Renal Trends in Cats Undergoing Continuous Renal Replacement Therapy with Adjunctive Molidustat Administration: A Retrospective Case Series
Continuous renal replacement therapy (CRRT) can precipitate anemia in critically ill patients, but temporal hematologic trends and anemia management strategies in cats remain poorly characterized. Medical records of three client-owned cats treated with CRRT for severe acute kidney injury with evidence of pre-existing chronic kidney disease at a single referral center were retrospectively reviewed. Hematologic variables (hematocrit, hemoglobin concentration, absolute reticulocyte count) and renal parameters (blood urea nitrogen, creatinine, phosphorus) were evaluated before, during, and after CRRT, along with the timing of CRRT sessions, whole blood transfusions, erythropoiesis-stimulating agent administration, and adjunctive molidustat use. All three cats demonstrated a progressive decline in hematocrit during the CRRT period despite repeated whole blood transfusions, with only transient post-transfusion improvement. Blood urea nitrogen and creatinine concentrations decreased promptly following CRRT initiation but showed variable rebound patterns during follow-up. Absolute reticulocyte counts increased after CRRT discontinuation in two cats, indicating preserved or recovering erythropoietic activity, while one cat with concurrent systemic inflammation showed a minimal response. Progressive anemia occurred consistently despite transfusion support, highlighting the multifactorial nature of anemia during feline CRRT. These descriptive findings provide clinically relevant insight into anemia progression during feline CRRT and may inform the design of future prospective studies.
- Open Access
- 1 April 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (4) , 1-7
Eltrombopag is well tolerated but provides no additional benefit in the treatment of canine primary immune-mediated thrombocytopenia
Objective: To evaluate the efficacy and tolerability of eltrombopag in dogs diagnosed with primary immune-mediated thrombocytopenia (pITP). Methods: Medical records from dogs diagnosed with pITP between January 2018 and March 2024 were retrospectively reviewed. Data collected included signalment, presenting signs, diagnostic findings, duration of hospitalization, time to platelet recovery (defined as days to achieve a platelet count ≥ 100,000/μL, with no evidence of bleeding), mortality, relapse incidence, transfusion requirements, and adverse events. Dogs were included if they received a combination of corticosteroids, vincristine, mycophenolate mofetil, and human immunoglobulin, with or without the addition of oral eltrombopag administered within 24 hours of diagnosis. Dogs were grouped on the basis of whether they did or did not receive eltrombopag (eltrombopag group vs control group), and results were compared between groups. Results: 18 dogs met the inclusion criteria (control group, n = 13; eltrombopag group, 5). Median time to platelet recovery, hospitalization, transfusion needs, and mortality did not differ significantly between groups. Eltrombopag was well tolerated, and adverse events, primarily gastrointestinal, were less frequent in the eltrombopag group. Conclusions: Eltrombopag was well tolerated as part of a multimodal treatment protocol for pITP in dogs. However, it was not associated with improved platelet recovery, shorter hospitalization, or reduced mortality compared with standard therapy alone. Clinical Relevance: This study provided evidence that eltrombopag may be safely incorporated into immunosuppressive regimens for canine pITP; however, its clinical benefit remains uncertain. Further research is required to determine its role in optimizing treatment for ITP in dogs.
- 1 April 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (4) , 1-7
Open AccessEltrombopag is well tolerated but provides no additional benefit in the treatment of canine primary immune-mediated thrombocytopenia
Objective: To evaluate the efficacy and tolerability of eltrombopag in dogs diagnosed with primary immune-mediated thrombocytopenia (pITP). Methods: Medical records from dogs diagnosed with pITP between January 2018 and March 2024 were retrospectively reviewed. Data collected included signalment, presenting signs, diagnostic findings, duration of hospitalization, time to platelet recovery (defined as days to achieve a platelet count ≥ 100,000/μL, with no evidence of bleeding), mortality, relapse incidence, transfusion requirements, and adverse events. Dogs were included if they received a combination of corticosteroids, vincristine, mycophenolate mofetil, and human immunoglobulin, with or without the addition of oral eltrombopag administered within 24 hours of diagnosis. Dogs were grouped on the basis of whether they did or did not receive eltrombopag (eltrombopag group vs control group), and results were compared between groups. Results: 18 dogs met the inclusion criteria (control group, n = 13; eltrombopag group, 5). Median time to platelet recovery, hospitalization, transfusion needs, and mortality did not differ significantly between groups. Eltrombopag was well tolerated, and adverse events, primarily gastrointestinal, were less frequent in the eltrombopag group. Conclusions: Eltrombopag was well tolerated as part of a multimodal treatment protocol for pITP in dogs. However, it was not associated with improved platelet recovery, shorter hospitalization, or reduced mortality compared with standard therapy alone. Clinical Relevance: This study provided evidence that eltrombopag may be safely incorporated into immunosuppressive regimens for canine pITP; however, its clinical benefit remains uncertain. Further research is required to determine its role in optimizing treatment for ITP in dogs.
- Open Access
- 1 July 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (4)
Retrospective Evaluation of Transcatheter Edge-To-Edge Mitral Valve Repair in Dogs With Myxomatous Mitral Valve Disease
Background: Transcatheter edge-to-edge repair (TEER) is an emerging minimally invasive mitral valve repair treatment for dogs with myxomatous mitral valve disease (MMVD), but reports on its outcomes are limited. Objective: Describe the clinical characteristics and complications in dogs with MMVD undergoing TEER. Animals: Twenty client-owned dogs with MMVD stages B2, C, and D. Methods: Retrospective case series. Cases were identified by review of hospital medical records between September 2023 and September 2024. Results: Twenty dogs underwent TEER; of these, 13 (65%) survived. Seven dogs died within 9 days because of mitral leaflet tear or single-leaflet device attachment (4/7 dogs, 57.1%), tracheal collapse (1/7 dogs, 14.3%), presumed post-procedure neurologic deficit with a history of hydrocephalus (1/7 dogs, 14.3%), and presumed cardiogenic shock (1/7 dogs, 14.3%). Significant reductions in vertebral heart score (11.6 [9.6–13.1] vs. 11.0 [8.3–11.9] vertebrae; p < 0.01), vertebral left atrial size (2.90 [2.1–3.6] vs. 2.60 [2.0–3.3] vertebrae; p < 0.01), left atrium-to-aortic root ratio (2.09 [1.5–2.5] vs. 1.69 [1.3–2.2]; p < 0.05), left ventricular end-diastolic diameter normalized for body weight (2.1 [1.5–2.3] vs. 1.76 [1.4–2.2]; p < 0.05), regurgitant fraction (77.83 [73.2–83.0] vs. 55.38 [20.5–73.6] %; p < 0.05), and regurgitant volume (3.96 [2.1–6.2] vs. 1.25 [0.4–3.5] ml/kg; p < 0.05) were observed 3 months after TEER. Conclusions and Clinical Importance: Transcatheter edge-to-edge repair resulted in a significant reduction in left atrium and ventricle size and should be further investigated as a potential treatment option for dogs with MMVD.
- 1 July 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (4)
Open AccessRetrospective Evaluation of Transcatheter Edge-To-Edge Mitral Valve Repair in Dogs With Myxomatous Mitral Valve Disease
Background: Transcatheter edge-to-edge repair (TEER) is an emerging minimally invasive mitral valve repair treatment for dogs with myxomatous mitral valve disease (MMVD), but reports on its outcomes are limited. Objective: Describe the clinical characteristics and complications in dogs with MMVD undergoing TEER. Animals: Twenty client-owned dogs with MMVD stages B2, C, and D. Methods: Retrospective case series. Cases were identified by review of hospital medical records between September 2023 and September 2024. Results: Twenty dogs underwent TEER; of these, 13 (65%) survived. Seven dogs died within 9 days because of mitral leaflet tear or single-leaflet device attachment (4/7 dogs, 57.1%), tracheal collapse (1/7 dogs, 14.3%), presumed post-procedure neurologic deficit with a history of hydrocephalus (1/7 dogs, 14.3%), and presumed cardiogenic shock (1/7 dogs, 14.3%). Significant reductions in vertebral heart score (11.6 [9.6–13.1] vs. 11.0 [8.3–11.9] vertebrae; p < 0.01), vertebral left atrial size (2.90 [2.1–3.6] vs. 2.60 [2.0–3.3] vertebrae; p < 0.01), left atrium-to-aortic root ratio (2.09 [1.5–2.5] vs. 1.69 [1.3–2.2]; p < 0.05), left ventricular end-diastolic diameter normalized for body weight (2.1 [1.5–2.3] vs. 1.76 [1.4–2.2]; p < 0.05), regurgitant fraction (77.83 [73.2–83.0] vs. 55.38 [20.5–73.6] %; p < 0.05), and regurgitant volume (3.96 [2.1–6.2] vs. 1.25 [0.4–3.5] ml/kg; p < 0.05) were observed 3 months after TEER. Conclusions and Clinical Importance: Transcatheter edge-to-edge repair resulted in a significant reduction in left atrium and ventricle size and should be further investigated as a potential treatment option for dogs with MMVD.
- Open Access
- 2 March 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (3) , 223
Preliminary Evaluation of NT-proBNP and cTnI as Predictors of Procedure Safety in Dogs Undergoing Transcatheter Edge-to-Edge Mitral Valve Repair
Myxomatous mitral valve disease (MMVD) in dogs can be treated with transcatheter edge-to-edge mitral valve repair (TEER), an emerging minimally invasive surgical technique. However, reports on prognostic markers for preoperative evaluation remain limited. This study evaluated the association of preoperative N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI) levels with procedure safety in dogs undergoing TEER. A retrospective analysis was conducted on 25 dogs diagnosed with stage C (n = 18) or D (n = 7) MMVD that underwent TEER between September 2023 and January 2025. Preoperative NT-proBNP and cTnI values were measured and compared between survivors and non-survivors. Among the survivors, 15 and 4 dogs were stages C and D, respectively. Among the non-survivors, three and three dogs were stages C and D, respectively. Non-survivors had higher median NT-proBNP levels (3557 pmol/L; range: 774–10,000) and cTnI levels (0.39 ng/mL; range: 0.22–0.51) than survivors (NT-proBNP: 1262.6 pmol/L, range: 500–8773; cTnI: 0.1 ng/mL, range: 0.01–3.6). However, the two groups showed no significant differences in NT-proBNP (p = 0.187) or cTnI (p = 0.869). Increased preoperative NT-proBNP and cTnI levels were not strong predictors of procedure safety in dogs with MMVD stages C and D undergoing TEER. Further studies with larger sample sizes and longer follow-up periods are needed to better evaluate the prognostic value of these biomarkers in this population.
- 2 March 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (3) , 223
Open AccessPreliminary Evaluation of NT-proBNP and cTnI as Predictors of Procedure Safety in Dogs Undergoing Transcatheter Edge-to-Edge Mitral Valve Repair
Myxomatous mitral valve disease (MMVD) in dogs can be treated with transcatheter edge-to-edge mitral valve repair (TEER), an emerging minimally invasive surgical technique. However, reports on prognostic markers for preoperative evaluation remain limited. This study evaluated the association of preoperative N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI) levels with procedure safety in dogs undergoing TEER. A retrospective analysis was conducted on 25 dogs diagnosed with stage C (n = 18) or D (n = 7) MMVD that underwent TEER between September 2023 and January 2025. Preoperative NT-proBNP and cTnI values were measured and compared between survivors and non-survivors. Among the survivors, 15 and 4 dogs were stages C and D, respectively. Among the non-survivors, three and three dogs were stages C and D, respectively. Non-survivors had higher median NT-proBNP levels (3557 pmol/L; range: 774–10,000) and cTnI levels (0.39 ng/mL; range: 0.22–0.51) than survivors (NT-proBNP: 1262.6 pmol/L, range: 500–8773; cTnI: 0.1 ng/mL, range: 0.01–3.6). However, the two groups showed no significant differences in NT-proBNP (p = 0.187) or cTnI (p = 0.869). Increased preoperative NT-proBNP and cTnI levels were not strong predictors of procedure safety in dogs with MMVD stages C and D undergoing TEER. Further studies with larger sample sizes and longer follow-up periods are needed to better evaluate the prognostic value of these biomarkers in this population.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Veterinary Science
- Vol. 26 (2) , e22
A novel thrombospondin-1 variant as a potential diagnostic biomarker and therapeutic target in canine mammary tumor and osteosarcoma cells
Hong Y, et al. J Vet Sci. 2025 Feb;26:e22. https://doi.org/10.4142/jvs.24165
- 1 January 2025
- Published by XMLink in Journal of Veterinary Science
- Vol. 26 (2) , e22
Open AccessA novel thrombospondin-1 variant as a potential diagnostic biomarker and therapeutic target in canine mammary tumor and osteosarcoma cells
Hong Y, et al. J Vet Sci. 2025 Feb;26:e22. https://doi.org/10.4142/jvs.24165
- Open Access
- 1 December 2024
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 85 (12) , 1-8
Preliminary evaluation of ionized magnesium levels in dogs on long-term esomeprazole administration
OBJECTIVE: To investigate the level of whole-blood ionized magnesium (iMg) in dogs with long-term use of proton pump inhibitors (PPIs). METHODS: The study included 10 client-owned dogs with esomeprazole administration over 6 months and 62 healthy dogs to determine de novo reference interval (RI) of iMg. Dogs that received esomeprazole for 6 months or longer were retrospectively reviewed to determine the incidence of hypo- or hypermagnesemia based on the de novo RI. Additionally, the iMg levels from the study group were compared with those of 20 age-, sex-, and body weight–matched controls from the 62 dogs. RESULTS: The median (range) duration of esomeprazole usage was 26 months (6 to 94). The de novo RI for iMg was determined as 0.73 (90% CI, 0.58 to 0.87) to 1.43 mg/dL (90% CI, 1.33 to 1.46). Based on the RI, none of the dogs with long-term esomeprazole developed hypo- or hypermagnesemia. The iMg from the matched control group was 1.17 mg/dL (90% CI, 0.83 to 1.46). The lowest iMg after 6 months of esomeprazole administration (90% CI, 0.96 mg/dL, 0.87 to 1.41) was significantly lower than the control group (P = .031). The iMg measured at the end of long-term esomeprazole treatment was 1.03 mg/dL (90% CI, 0.87 to 1.41) and not significantly different from the control group (P = .179). CONCLUSIONS: Ionized hypomagnesemia was not observed after long-term use of esomeprazole in the small number of dogs included in this study. Robust RI needs to be determined in future studies to investigate the incidence of hypomagnesemia in dogs with long-term use of PPIs. CLINICAL RELEVANCE: Future studies in a larger number of dogs are warranted to confirm the findings from the present study and to determine whether the long-term use of esomeprazole in dogs is at risk of developing ionized hypomagnesemia.
- 1 December 2024
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 85 (12) , 1-8
Open AccessPreliminary evaluation of ionized magnesium levels in dogs on long-term esomeprazole administration
OBJECTIVE: To investigate the level of whole-blood ionized magnesium (iMg) in dogs with long-term use of proton pump inhibitors (PPIs). METHODS: The study included 10 client-owned dogs with esomeprazole administration over 6 months and 62 healthy dogs to determine de novo reference interval (RI) of iMg. Dogs that received esomeprazole for 6 months or longer were retrospectively reviewed to determine the incidence of hypo- or hypermagnesemia based on the de novo RI. Additionally, the iMg levels from the study group were compared with those of 20 age-, sex-, and body weight–matched controls from the 62 dogs. RESULTS: The median (range) duration of esomeprazole usage was 26 months (6 to 94). The de novo RI for iMg was determined as 0.73 (90% CI, 0.58 to 0.87) to 1.43 mg/dL (90% CI, 1.33 to 1.46). Based on the RI, none of the dogs with long-term esomeprazole developed hypo- or hypermagnesemia. The iMg from the matched control group was 1.17 mg/dL (90% CI, 0.83 to 1.46). The lowest iMg after 6 months of esomeprazole administration (90% CI, 0.96 mg/dL, 0.87 to 1.41) was significantly lower than the control group (P = .031). The iMg measured at the end of long-term esomeprazole treatment was 1.03 mg/dL (90% CI, 0.87 to 1.41) and not significantly different from the control group (P = .179). CONCLUSIONS: Ionized hypomagnesemia was not observed after long-term use of esomeprazole in the small number of dogs included in this study. Robust RI needs to be determined in future studies to investigate the incidence of hypomagnesemia in dogs with long-term use of PPIs. CLINICAL RELEVANCE: Future studies in a larger number of dogs are warranted to confirm the findings from the present study and to determine whether the long-term use of esomeprazole in dogs is at risk of developing ionized hypomagnesemia.
- Open Access
- 31 December 2023
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 40 (6) , 445-451
Surgery and Metronomic Chemotherapy in a Pet Rabbit (Oryctolagus cuniculus) with Mammary Gland Adenocarcinoma
Jihee Hong, Jeong-Min Lee, Ji-Young Lee, Han-Joon Lee, Dong-Kwan Lee, Joong-Hyun Song, Kun-Ho Song. J Vet Clin 2023;40:445-51. https://doi.org/10.17555/jvc.2023.40.6.445
- 31 December 2023
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 40 (6) , 445-451
Open AccessSurgery and Metronomic Chemotherapy in a Pet Rabbit (Oryctolagus cuniculus) with Mammary Gland Adenocarcinoma
Jihee Hong, Jeong-Min Lee, Ji-Young Lee, Han-Joon Lee, Dong-Kwan Lee, Joong-Hyun Song, Kun-Ho Song. J Vet Clin 2023;40:445-51. https://doi.org/10.17555/jvc.2023.40.6.445
- Open Access
- 28 December 2023
- Published by The Korean Society of Veterinary Science (KJVR) in Korean Journal of Veterinary Research
- Vol. 63 (4) , e38
Treatment of canine CD3+/CD21+/CD45- T-zone lymphoma with chlorambucil and prednisolone in two dogs: case reports
Canine T-zone lymphoma (TZL) is an indolent form of T-cell lymphoma. Conservative management is usually recommended; however, chemotherapy may be considered for symptomatic or progressive cases. Herein, we describe two dogs with generalized peripheral lymphadenopathy and peripheral blood lymphocytosis at presentation. One dog presented with gross lesions on the tongue. Flow cytometric immunophenotyping and cytological examinations demonstrated findings consistent with those of TZL. Chemotherapy with chlorambucil and prednisolone was administered, which resulted in improvement of the condition without any adverse events. Chemotherapy with chlorambucil may be considered as an appropriate choice for treating canine TZL.
- 28 December 2023
- Published by The Korean Society of Veterinary Science (KJVR) in Korean Journal of Veterinary Research
- Vol. 63 (4) , e38
Open AccessTreatment of canine CD3+/CD21+/CD45- T-zone lymphoma with chlorambucil and prednisolone in two dogs: case reports
Canine T-zone lymphoma (TZL) is an indolent form of T-cell lymphoma. Conservative management is usually recommended; however, chemotherapy may be considered for symptomatic or progressive cases. Herein, we describe two dogs with generalized peripheral lymphadenopathy and peripheral blood lymphocytosis at presentation. One dog presented with gross lesions on the tongue. Flow cytometric immunophenotyping and cytological examinations demonstrated findings consistent with those of TZL. Chemotherapy with chlorambucil and prednisolone was administered, which resulted in improvement of the condition without any adverse events. Chemotherapy with chlorambucil may be considered as an appropriate choice for treating canine TZL.
- Open Access
- 1 September 2023
- Published by Research Institute of Veterinary Medicine in Journal of Biomedical and Translational Research
- Vol. 24 (3) , 105-110
Unsuccessful treatment of granulomatous meningoencephalomyelitis in a dog with the combination of multiple immunosuppressive agents
Journal of Biomedical and Translational Research
- 1 September 2023
- Published by Research Institute of Veterinary Medicine in Journal of Biomedical and Translational Research
- Vol. 24 (3) , 105-110
Open AccessUnsuccessful treatment of granulomatous meningoencephalomyelitis in a dog with the combination of multiple immunosuppressive agents
Journal of Biomedical and Translational Research